REDUCER-I: An Observational Study of the Neovasc Reducer™ System

Inclusion Criteria - ALL Arms: * Subject has been informed about the study and provides written informed consent prior to enrollment * Subject is willing to comply with specified follow-up evaluations Inclusion Criteria - Arm 1: * Symptomatic Coronary Artery Disease (CAD) with chronic refractory angina pectoris despite attempted optimal medical therapy * Subject has limited treatment options for revascularization by Coronary Artery Bypass Grafting (CABG) or by Percutaneous Coronary Intervention (PCI) * Evidence of reversible myocardial ischemia * Left Ventricular ejection fraction (LVEF) greater than or equal to 30% * Male or non-pregnant female Inclusion Criteria - Arm 2: * Subjects previously implanted in the Reducer (treatment) arm of the COSIRA study Inclusion Criteria - Arm 3: * Subjects in whom the Reducer was implanted under CE Mark (unrelated to the COSIRA study), prior to enrollment in the Reducer-I study Exclusion Criteria - Arm 1: * Acute coronary syndrome within three months prior to enrollment * Recent successful revascularization by PCI or CABG within six months prior to enrollment * Recent unsuccessful PCI (no relief from symptoms) within 30 days prior to enrollment * Unstable angina (recent onset angina, crescendo angina, or rest angina with electrocardiogram \[ECG\] changes) during the 30 days prior to enrollment * Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the three months prior to enrollment * Severe chronic o…